CN114601854A - 半枫荷或其提取物在制备抗脑缺血药物中的应用 - Google Patents
半枫荷或其提取物在制备抗脑缺血药物中的应用 Download PDFInfo
- Publication number
- CN114601854A CN114601854A CN202210331183.XA CN202210331183A CN114601854A CN 114601854 A CN114601854 A CN 114601854A CN 202210331183 A CN202210331183 A CN 202210331183A CN 114601854 A CN114601854 A CN 114601854A
- Authority
- CN
- China
- Prior art keywords
- extract
- semiliquidambar cathayensis
- cathayensis
- semiliquidambar
- cerebral ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000407905 Semiliquidambar cathayensis Species 0.000 title claims abstract description 88
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 41
- 201000006474 Brain Ischemia Diseases 0.000 title claims abstract description 36
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title abstract description 23
- 238000010438 heat treatment Methods 0.000 claims abstract description 24
- 238000000605 extraction Methods 0.000 claims abstract description 15
- 238000002791 soaking Methods 0.000 claims abstract description 10
- 239000006286 aqueous extract Substances 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000012153 distilled water Substances 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 241000142952 Hamamelidaceae Species 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 2
- 241001596270 Aizoon Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 18
- 230000002490 cerebral effect Effects 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003188 neurobehavioral effect Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000407906 Semiliquidambar Species 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229930063422 Bilobalide A Natural products 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241001546929 Campsis grandiflora Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 238000010155 Games-Howell test Methods 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 241000906682 Hemsleya Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000802381 Polyrhachis vicina Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000305548 Pterocarya stenoptera Species 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- SQOJOAFXDQDRGF-ZMVGXLHTSA-N ginkgolide b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-ZMVGXLHTSA-N 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000000745 ion overload Effects 0.000 description 1
- 230000004171 ischemic cascade Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种半枫荷或其提取物在制备抗脑缺血药物中的应用，所述半枫荷为金缕梅科半枫荷(学名：Semiliquidambar cathayensis H.T.Chang.)的干燥根，半枫荷提取物为半枫荷的水提物或半枫荷的有机溶剂提取物，半枫荷提取物的提取方法为：取半枫荷，加入溶剂进行浸泡处理，再加热进行提取，合并多次提取的药液进行浓缩即得。本发明首次发现半枫荷或其提取物具有明显的减轻脑缺血损伤作用，具有制备预防或治疗脑缺血及其相关疾病的药物制剂的成药潜力，且药物制剂的制备方法简单，成本低，成药经济效益好。
Description
技术领域
本发明属于中医药技术领域，具体涉及一种半枫荷或其提取物在制备抗脑缺血药物中的应用。
背景技术
脑卒中包括缺血性脑卒中和出血性脑卒中，缺血性脑卒中约占60%-80%。缺血性脑卒中是由局部脑供血、供氧不足或中断引起的脑部局灶性功能障碍，常见的有短暂脑缺血发作、脑栓塞、脑血栓等，是世界范围内重大的脑血管疾病，是临床常见的为危重病、多发病，往往预后较差，具有发病率和致残致死率高的特点，目前尚缺乏治疗或延缓脑缺血损伤的有效方法。缺血-再灌注损伤(ischemia reperfusion injury，IRI) 是指组织在遭受一定时间缺血，恢复血液供应后，组织损伤程度加重的病理现象。缺血引起的脑组织缺氧以及缺血再灌注，触发了一系列脑缺血级联反应，最终导致神经元死亡和神经功能障碍。
现代医学研究关于脑缺血的发生机制有能量代谢障碍、血小板聚集、血管收缩及微循环障碍、自由基损伤、兴奋性氨基酸毒性作用、细胞内钙离子超载、炎症损伤、NO和NOS的作用、细胞凋亡等，病理生理机制复杂；脑缺血损伤是由于脑部血液循环障碍，造成细胞能量代谢衰竭，从而启动的损伤级联反应的结果。该损伤级联反应主要涉及兴奋性神经毒性、酸中毒、炎症反应、氧化和硝化应激、围梗死去极化、细胞凋亡等方面。现代医学防治脑缺血多采用药物性干预，临床可用于防治脑缺血的药物主要有抗血小板药的阿司匹林、氯吡格雷、噻氯匹定和阿司匹林 - 双嘧达莫，抗凝剂的肝素、低分子肝素，口服抗凝剂的华法林、双香豆素针，溶栓的尿激酶 (UK)、链激酶 (SK)，血管扩张剂麦角溴烟酯，自由基清除剂超氧化物歧化酶、地塞米松、甘露醇、维生素E，钙拮抗剂尼莫地平，谷氨酸受体拮抗剂，NOS抑制剂及他汀类药物等，其中以阿司匹林抗血小板聚集的应用最多。但是现有的药物由于价格较贵且给药方式受限、副作用多而不适宜反复应用或因用药时间长、给药剂量大等使应用受到了限制。
近些年来，国内外学者将目光投向天然药物（中药或中药制剂）的开发，中药治疗脑血管疾病的历史悠久，且中药具有副作用小等优点；中药保护缺血性脑损伤多通过降低兴奋性神经递质和酸的毒性作用、抑制脂质过氧化和硝化反应、减轻炎症反应、促进血管新生和抑制细胞凋亡等途径来实现，具有多靶点、多层次、多环节的脑保护作用，能从多条路径干预脑缺血，减轻脑缺血再灌注的损伤。如，河南中医学院在专利CN 101978987 B、CN102008521 B、CN 103417679 B分别提出了冬凌草提取物、凌霄花提取物、玫瑰花总黄酮在制备治疗抗脑缺血药物中的应用；西北大学在专利CN 103800826 B提出了黄姜提取物在制备抗脑缺血药物中的应用；广西壮族自治区中医药研究院在专利CN 112245456 A提出了一种拟黑多刺蚁提取物在制备抗脑缺血药物中应用。尚远宏和徐晓玉总结了截至2013年近10 年来对脑缺血具有保护作用的中药及其提取物，包括植物药、动物药和矿物药共35 种单味药，国内外文献中的实验研究都表明从中药得到的单体成分(如银杏内酯B、川芎嗪、人参皂苷 Rb3和丹参酮Ⅱ等)或提取物 (如山楂醇提物、当归水提物和地龙提取物等)，及多种药物组方(如银杏达莫注射液、参龙健脑胶囊和参芎注射液等)可通过脑缺血的病理生理机制中的各种途径来实现对缺血性脑损伤的保护作用，充分说明中药及其提取物对于缺血性脑损伤保护作用的研究前景广阔（见尚远宏,徐晓玉.中药及其提取物对脑缺血保护作用的实验研究进展[J]，《中国中药杂志》2013年8期）。
半枫荷（学名：Semiliquidambar cathayensis H. T. Chang.）为金缕梅科半枫荷属植物，别名金缕半枫荷、木荷树、小叶半枫荷，国家二级保护植物，现残存于中国南部和东南山区。半枫荷其根、茎枝、叶及花蜜均可入药，具有祛风除湿、舒筋活血的功效，民间用于治疗风湿性关节炎、跌打损伤、瘀积肿痛、产后风瘫等症；现代药理研究表明，金缕半枫荷根的醇提物具有抗炎镇痛、活血化瘀作用，枝干多酚具有抗菌和抗氧能力，半枫荷的活性成分齐墩果酸对病毒性肝炎的抗原具有抑制活性。梁伟江等人采用持续力竭性游泳血瘀模型，检测舌象、全血黏度、血浆黏度、红细胞聚集指数、血小板数、TT、PT、APTT、FIB等指标，考察了半枫荷各极性提取物的活血化瘀作用。结果：不同极性半枫荷提取物均能显著改善大鼠的血瘀状态、血液流变学及凝血相关指标(P＜0.05或P＜0.01)，其中以水部位的作用最强，且水部位的作用表现出明显的量效关系。结论：半枫荷提取物均具有显著的活血化瘀作用，其活血化瘀的有效部位为水部位（梁伟江，卢海啸，曾孟，等.半枫荷提取物对血瘀模型大鼠的影响[J]，《中药材》2015年2期）。 现有文献资料显示半枫荷具有丰富的药理活性，可用于制备抗乙型肝炎病毒、活血化瘀、抗炎镇痛、治疗骨关节炎等方面的药物，但在半枫荷抗脑缺血方面，目前未见有相关的报道。
发明内容
本发明的目的是提供一种半枫荷或其提取物在制备抗脑缺血药物中的应用，本发明首次发现半枫荷或其提取物具有明显的减轻脑缺血损伤的活性，具有制备预防或治疗脑缺血及其相关疾病的药物制剂的成药潜力，且药物制剂的制备方法简单，成本低，成药经济效益好。
为实现上述目的，本发明采用如下技术方案：
半枫荷或其提取物在制备抗脑缺血药物中的应用。
所述半枫荷为金缕梅科半枫荷(Semiliquidambar cathayensis H. T. Chang.)的干燥根，半枫荷提取物为半枫荷的水提物或半枫荷的有机溶剂提取物。
所述半枫荷水提物的提取方法为：
（1）取半枫荷，加入4～8倍质量蒸馏水先浸泡40～80min，然后加热至80～100℃提取40～80min，过滤，收集滤液；
（2）滤渣再加入4～8倍质量蒸馏水加热至80～100℃提取40～80min，过滤，收集滤液；
（3）重复提取滤渣1～3次，合并多次提取得到的滤液并进行浓缩，即得。
所述半枫荷的有机溶剂提取物为半枫荷的乙醇提取物，提取方法为：
（1）取半枫荷，加入4～8倍量体积浓度为85～95%的乙醇先浸泡40～80min，然后加热进行回流提取40～80min，过滤，收集滤液；
（2）滤渣再加入4～8倍量体积浓度为85～95%的乙醇，继续加热进行回流提取40～80min，过滤，收集滤液；
（3）重复提取滤渣1～3次，合并多次提取得到的滤液并进行浓缩回收乙醇，即得。
以上所述的半枫荷提取物添加常规辅料，按照常规工艺制成临床可接受的用于预防或治疗脑缺血及其相关疾病的药物制剂。
所述制剂包括片剂、胶囊剂、滴丸或颗粒剂。
所述的常规辅料包括淀粉、乳糖、微晶纤维素、糊精、磷酸钙、聚乙二醇-4000、聚乙二醇-6000、豆油、蜂胶、羧甲基纤维素钠、羟丙纤维素或交联聚维酮中一种以上。
本发明的有益效果是：
1、本发明首次发现半枫荷及半枫荷提取物具有明显的抗脑缺血活性，具有制备预防或治疗脑缺血及其相关疾病的药物制剂的成药潜力，为开发抗脑缺血创新药物提供了新的物质基础，具有潜在且巨大的社会效益和经济效益。
2、本发明的半枫荷资源丰富，来源广，半枫荷提取物的提取制备方法简单易行，成本低、污染小，有利于节能减排条件下的大规模生产，产业化前景好。
3、本发明通过研究半枫荷提取物对脑缺血再灌注损伤大鼠的治疗作用，证明了半枫荷提取物可以改善缺血大鼠神经功能，降低大鼠脑梗死面积和脑水肿，有力证明了本发明的半枫荷提取物对脑缺血损伤具有明显的拮抗作用，可用于制备抗脑缺血药物。
4、本发明的半枫荷或半枫荷提取物还具有祛风除湿、舒筋活血等功效，可用于风湿性关节炎、跌打损伤、瘀积肿痛、产后风瘫等症，可以在用于预防或治疗脑缺血的同时起到治疗其他合并症的效果。
5、半枫荷可以与其他药材进行配伍组成复方药用于预防或治疗脑缺血，还可以将半枫荷提取物与辅料混合制成片剂、胶囊、滴丸或颗粒剂，这些制剂较为方便服用，能单独或者搭配其他药剂服用，通过内服能将药性通过血液快速输送至病症部位进行有效治疗。
附图说明
图1半枫荷提取物及其他组对脑缺血大鼠脑含水量的影响作用；
图2半枫荷提取物及其他组对脑缺血大鼠神经行为学评分的影响作用；
图3半枫荷提取物及其他组对脑缺血大鼠脑梗塞率的影响作用；
图4各组脑缺血大鼠脑TTC 染色结果。
具体实施方式
为了更加详细的介绍本发明，下面结合实施例，对本发明做进一步说明。
实施例1 半枫荷提取物的制备
取半枫荷1kg，加入6L蒸馏水浸泡60min，然后加热至80℃提取60min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至80℃提取60min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至80℃提取60min，过滤，收集滤液；合并3次提取液，浓缩至1.0g/mL，即得。
实施例2 半枫荷提取物的制备
取半枫荷1kg，加入6L蒸馏水浸泡60min，然后加热至90℃提取60min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至90℃提取60min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至90℃提取60min，过滤，收集滤液；合并3次提取液，浓缩至1.1g/mL，即得。
实施例3 半枫荷提取物的制备
取半枫荷1kg，加入6L蒸馏水浸泡60min，然后加热至98℃提取60min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至98℃提取60min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至98℃提取60min，过滤，收集滤液；合并3次提取液，浓缩至1.2g/mL，即得。
实施例4 半枫荷提取物的制备
取半枫荷1kg，加入8L蒸馏水浸泡80min，然后加热至80℃提取80min，过滤，收集滤液；滤渣再加入6L蒸馏水加热至90℃提取60min，过滤，收集滤液；滤渣再加入4L蒸馏水加热至98℃提取40min，过滤，收集滤液；合并3次提取液，浓缩至1.0～1.2g/mL，即得。
实施例5 半枫荷提取物的制备
取半枫荷1kg，加入6L体积浓度为90%的乙醇先浸泡60min，然后加热进行回流提取60min，过滤，收集滤液；滤渣再加入6L体积浓度为90%的乙醇，继续加热进行回流提取60min，过滤，收集滤液；滤渣再加入6L体积浓度为90%的乙醇，继续加热进行回流提取60min，过滤，收集滤液；合并3次提取液并进行浓缩回收乙醇成膏，即得。
实施例6 半枫荷提取物片剂的制备
【处方】由实施例3的方法制得的半枫荷水提物（取相当于半枫荷药材3kg的量）、干淀粉550g；
【制备方法】将所得的半枫荷水提物、干淀粉混匀，加入适量羧甲基纤维素钠、滑石粉，制成颗粒，干燥，压制成1000片，所得的半枫荷提取物片，每片含半枫荷药材3g。
以上所述的干淀粉、羧甲基纤维素钠和滑石粉均可在市场上购买得到。
实施例7 半枫荷提取物胶囊的制备
【处方】由实施例3的方法制得的半枫荷水提物（取相当于半枫荷药材3kg的量）、干淀粉550g；
【制备方法】将所得的半枫荷水提物、干淀粉混匀，加入适量羧甲基纤维素钠、滑石粉，制成颗粒，干燥，分装成1000 粒，所得的半枫荷提取物胶囊，每粒含半枫荷药材3g。
以上所述的干淀粉、羧甲基纤维素钠和滑石粉均可在市场上售得到。
实施例8 半枫荷提取物颗粒剂的制备
【处方】由实施例3的方法制得的半枫荷水提物（取相当于半枫荷药材10kg的量）、干淀粉550g；
【制备方法】将所得的半枫荷水提物、干淀粉混匀，加入适量羧甲基纤维素钠、滑石粉，制成颗粒，干燥，分装成1000袋，所得的半枫荷提取物颗粒，每袋含半枫荷药材10g。
以上所述的干淀粉、羧甲基纤维素钠和滑石粉均可在市场上购买得到。
药性试验
为了验证本发明半枫荷提取物的抗脑缺血损伤作用，本申请人进行了以下试验：
1、半枫荷提取物对大鼠脑缺血再灌注损伤的治疗作用
供试品：所述半枫荷提取物均是由实施例3中所述方法制备而成。
处理方法：
（1）大鼠大脑中动脉阻塞再灌注（MCAO/R）模型的建立
取SD 大鼠按体重随机分4组：模型组、阳性药组（银杏二萜内酯葡胺注射液，1.25mg/kg）、半枫荷组（1800mg/kg）、假手术组。假手术组和模型组两组给予等容积的溶剂，其余给药组每天灌胃给药1次，连续给药12天，于末次给药1h后开始造模。采用线栓法建立脑缺血/再灌注模型。线栓推进右颈内动脉，并堵塞脑中动脉，90min 后，将栓线移除，恢复血流，建立脑内再灌注状态。
（1）神经行为学评分
大鼠再灌后24 h进行行为学观察，按表1标准进行Bederson评分
（2）大鼠脑梗死面积和脑含水量的检测
戊巴比妥钠麻醉后取出全脑。将全脑置于-20℃冰箱冷冻20min。至大鼠脑变硬时，用锋利的刀片在视交叉及其前后各2mm处，做冠状切片，将脑组织切成五片，迅速将切好的脑片置于含有1% TTC的PBS缓冲溶液中，37℃避光温孵10min。10min后轻轻取出脑片，按顺序排列好，擦干脑片周围的水分，用数码相机进行拍照。数码照片使用Image J图像分析软件进行分析，计算梗死率的公式如下：
梗死率（%）=（缺血对侧脑面积-缺血侧非梗死区脑面积）/缺血对侧脑面积×100%
染色后的脑组织进行称重，此时重量为脑组织湿重，随后置于110℃烘箱24 h后称重，此时重量为脑组织干重，计算脑组织含水量的公式如下：
脑组织含水量（%）=（湿重-干重）/湿重×100%
（3）统计学方法
所有数据以平均值±标准差（mean ± SD）表示，spss软件（版本号19.0）进行统计分析。实验组间差异采用非参数检验对神经行为学评分进行统计分析，其余采用单因素方差分析（one-way ANOVA），当方差齐性时，选择LSD检验，当方差不齐性时，选择GamesHowell检验，P<0.05为差异有显著性，P<0.01为差异有极显著性。
结果：如图1-3所示，与假手术组相比，模型组大鼠神经行为学评分、脑梗死率和脑含水量极显著升高（P<0.01）。与模型组相比，阳性药组、半枫荷组大鼠神经行为学评分显著降低（P<0.05，P<0.01）；阳性药组、半枫荷组大鼠脑梗死率极显著降低（P<0.01，P<0.01）；阳性药组、半枫荷组大鼠脑含水量极显著降低（P<0.01，P<0.01）。脑TTC梗死染色结果如图4所示。注：## P<0.01 vs.假手术组；** P<0.05，** P<0.01 vs.模型组。
Claims (8)
1.半枫荷或其提取物在制备抗脑缺血药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述半枫荷为金缕梅科半枫荷的干燥根，半枫荷提取物为半枫荷的水提物或半枫荷的有机溶剂提取物。
3.根据权利要求2所述的应用，其特征在于，所述半枫荷水提物的提取方法为：
（1）取半枫荷，加入4～8倍质量蒸馏水先浸泡40～80min，然后加热至80～100℃提取40～80min，过滤，收集滤液；
（2）滤渣再加入4～8倍质量蒸馏水加热至80～100℃提取40～80min，过滤，收集滤液；
（3）重复提取滤渣1～3次，合并多次提取得到的滤液并进行浓缩，即得。
4.根据权利要求2所述的应用，其特征在于，所述半枫荷的有机溶剂提取物为半枫荷的乙醇提取物。
5.根据权利要求4所述的应用，其特征在于，所述半枫荷的乙醇提取物的提取方法为：
（1）取半枫荷，加入4～8倍量体积浓度为85～95%的乙醇先浸泡40～80min，然后加热进行回流提取40～80min，过滤，收集滤液；
（2）滤渣再加入4～8倍量体积浓度为85～95%的乙醇，继续加热进行回流提取40～80min，过滤，收集滤液；
（3）重复提取滤渣1～3次，合并多次提取得到的滤液并进行浓缩回收乙醇，即得。
6.根据权利要求1～5任意一项所述的应用，其特征在于，半枫荷提取物添加常规辅料，按照常规工艺制成临床可接受的用于预防或治疗脑缺血的药物制剂。
7.根据权利要求6所述的应用，其特征在于，所述制剂包括片剂、胶囊剂、滴丸或颗粒剂。
8.根据权利要求6所述的应用，其特征在于，所述的常规辅料包括淀粉、乳糖、微晶纤维素、糊精、磷酸钙、聚乙二醇-4000、聚乙二醇-6000、羧甲基纤维素钠、羟丙纤维素或交联聚维酮中一种以上。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210331183.XA CN114601854A (zh) | 2022-03-31 | 2022-03-31 | 半枫荷或其提取物在制备抗脑缺血药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210331183.XA CN114601854A (zh) | 2022-03-31 | 2022-03-31 | 半枫荷或其提取物在制备抗脑缺血药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114601854A true CN114601854A (zh) | 2022-06-10 |
Family
ID=81867699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210331183.XA Pending CN114601854A (zh) | 2022-03-31 | 2022-03-31 | 半枫荷或其提取物在制备抗脑缺血药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114601854A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105911192A (zh) * | 2016-06-06 | 2016-08-31 | 玉林师范学院 | 一种半枫荷活血化瘀活性部位的提取方法及指纹图谱检测方法 |
| CN112274541A (zh) * | 2020-12-18 | 2021-01-29 | 广西壮族自治区中医药研究院 | 半枫荷或其提取物在制备抗肿瘤药物中的应用 |
| CN112274542A (zh) * | 2020-12-18 | 2021-01-29 | 广西壮族自治区中医药研究院 | 半枫荷或其提取物在制备抗抑郁症药物中的应用 |
-
2022
- 2022-03-31 CN CN202210331183.XA patent/CN114601854A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105911192A (zh) * | 2016-06-06 | 2016-08-31 | 玉林师范学院 | 一种半枫荷活血化瘀活性部位的提取方法及指纹图谱检测方法 |
| CN112274541A (zh) * | 2020-12-18 | 2021-01-29 | 广西壮族自治区中医药研究院 | 半枫荷或其提取物在制备抗肿瘤药物中的应用 |
| CN112274542A (zh) * | 2020-12-18 | 2021-01-29 | 广西壮族自治区中医药研究院 | 半枫荷或其提取物在制备抗抑郁症药物中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| 梁伟江等: "半枫荷提取物对血瘀模型大鼠的影响", 《中药材》 * |
| 樊淑彦等: "中药治疗缺血性脑卒中的研究进展", 《脑与神经疾病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9138449B2 (en) | Medicinal composition for liver diseases | |
| WO2018058261A1 (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| WO2006118553A1 (en) | Compositions comprising natural agents for the treatment of hiv-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents | |
| CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
| CN114601854A (zh) | 半枫荷或其提取物在制备抗脑缺血药物中的应用 | |
| CN114796290B (zh) | 香青藤或其提取物在制备抗脑缺血药物中的应用 | |
| EP3141256B1 (en) | Hepatoprotective traditional chinese medicine composition, and preparation method thereof | |
| CN112274542B (zh) | 半枫荷水提物在制备抗抑郁症药物中的应用 | |
| CN101439069B (zh) | 豨莶草叶提取物、其制备方法及其应用 | |
| CN103285022A (zh) | 用于制备治疗多囊卵巢综合征的中药单体组合物及其制备方法 | |
| TW201902504A (zh) | 南洋山蘇水萃物的用途 | |
| CN102188483A (zh) | 一种治疗咽喉炎的提取物及其制备方法 | |
| CN113350390A (zh) | 美花风毛菊总倍半萜内酯及制备方法和其药物用途 | |
| CN102641382B (zh) | 一种治疗脂溢性脱发的药物组合物及其制备方法 | |
| CN112245456B (zh) | 一种拟黑多刺蚁提取物在制备抗脑缺血药物中应用 | |
| CN114736182B (zh) | 一种抗心肌缺血再灌注损伤的化合物和傣药组合物及其应用 | |
| CN113521131B (zh) | 一种用于缺血性心肌病的中药组合物及其应用 | |
| CN104547026A (zh) | 一种丹参叶三七提取物的制备方法及其应用 | |
| CN106138990B (zh) | 一种乳癖康固体分散体制剂及其制备方法 | |
| CN103989966B (zh) | 一种防治偏头痛疾病的药物组合及其制备方法与应用 | |
| CN103239569B (zh) | 蔓茎堇菜在制备治疗病毒性肝炎药物中的应用 | |
| CN113967233B (zh) | 一种抗肺纤维化的药物组合物及其制备方法 | |
| CN112587572B (zh) | 壮药五叶泡醇提物作为制备抗痛风性关节炎药物的用途 | |
| CN106729577B (zh) | 一种治疗风湿着痹症的中药组合物及制备方法 | |
| CN105250498A (zh) | 治疗风湿性关节炎的外用组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |